title: Short-term recovery of chemotherapy-induced peripheral neuropathy after treatment for pediatric non-CNS cancer.
abstract: Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent side effect of pediatric cancer treatment. The presentation of CIPN, trajectory and completeness of recovery over the first 6 months postchemotherapy, and the influence of patient and treatment characteristics on recovery are described.
  
  
  
  Sixty-seven children and adolescents treated for non-CNS cancers were evaluated for CIPN using the pediatric modified total neuropathy score (ped-mTNS) while on treatment and 3 and 6 months postchemotherapy. Differences between diagnostic groups and treatment type were evaluated as well as change in scores over time. Risk factors for on-treatment and persistent CIPN at 6 months were identified.
  
  
  
  Overall, ped-mTNSs were in the abnormal range for 86.5% during treatment and scores decreased over time (initial 9.3 ± 0.6, 6 months 4.3 ± 0.4; F = 38.14, P < 0.001). By 6 months posttreatment, mean scores and percentage of children with abnormal scores were reduced to 2.4 ± 0.3 and 11.5%, respectively, in the ALL group, but remained higher at 5.7 ± 0.7 and 57%, respectively, for lymphoma, and 5.2 ± 1.0 and 60%, respectively, for other solid tumors. At 6 months posttreatment, light touch deficits and foot strength deficits remained in 19.4 and 59.7%, respectively, compared with only 4.9 and 9.8% of the control population. Subjects who were older at exposure, female, or who received etoposide in addition to vincristine were at higher risk for on-treatment CIPN. On-treatment sensory abnormalities were associated with increased risk of persistent CIPN.
  
  
  
  While CIPN improves in most pediatric patients, significant numbers, especially those treated for lymphoma or other solid tumors, have remaining neuropathic signs and symptoms 6 months posttreatment.
authors: Department of Physical Therapy, St Catherine University, Minneapolis, Minnesota.|Cancer and Blood Disorders Program, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota.
authors: Laura S
authors: LS
authors: Gilchrist
authors: Developmental and Rehabilitation Services, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota.
authors: Lynn R
authors: LR
authors: Tanner
authors: Department of Epidemiology and Cancer Control, St Jude Research Hospital, Memphis, Tennesee.
authors: Kirsten K
authors: KK
authors: Ness
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis* / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010523:Peripheral Nervous System Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D011379:Prognosis; D011788:Quality of Life; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents
keywords: neurotoxicity; pediatric cancer